SyntheX aims to expand drug design for the treatment of cancer and rare diseases by implementing a platform for the discovery of new classes of therapeutics that target the weakness in cancer cells (synthetic lethality).
Company (Alive / Active)
953 Indiana St
San Francisco, 94107
California, United States
|Investor||Investor Type||Location||Participating Rounds|